ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

IL-21, a Potential Target of Active Rejection in Renal Transplantation

J. Shen, R. Wang, L. Guo, J. Lv, J. Wu, J. Chen

Kidney Disease Center, First Affiliated Hospital of Zhejiang University, Hangzhou, China

Meeting: 2020 American Transplant Congress

Abstract number: A-347

Keywords: Kidney transplantation, Tolerance

Session Information

Session Name: Poster Session A: Acute Rejection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Rejection remains an obstacle to overcome after transplantation. IL-21 is the most potent stimulators of driving GC B cells into plasma cells. Basic researches about the role of IL-21 in immune status after transplantation are limited. A higher level of IL-21 in patients with stable status after transplantation was observed by Luminex assay, which triggered our interests in studying the function of IL-21 in kidney transplantation.

*Methods: Luminex assay was used to analyze the cytokine signature and antibody class-switching level in patients with no rejection (NR)(n=30), TCMR (n=28), and ABMR (n=8). Then, a rodent kidney transplantation model was established with injected exogenous IL-21 to mimic the serum IL-21 level in stable patients. The histopathology evaluation, cytokine levels, and lymphocytes were analyzed to illuminate the mechanism of allograft rejection.

*Results: A distinct cytokine signature in patients with active rejection was found. The IL-21 level in NR cohort was significantly higher than both TCMR (P <0.001) and ABMR (P =0.005) cohorts. An enhanced antibody class switching rate was observed in both rejection cohorts, TCMR and ABMR. In contrast, exogenous IL-21 administration accelerated the active rejection after KT. Further analysis revealed that the increase of IL-21 in spleen induced proliferation of CD4+ T cells and CD19+ cells after IL-21 treatment.

*Conclusions: IL-21 plays a critical role in active rejection after kidney transplantation, that could be a potential therapy target of active rejection.

 border=

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shen J, Wang R, Guo L, Lv J, Wu J, Chen J. IL-21, a Potential Target of Active Rejection in Renal Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/il-21-a-potential-target-of-active-rejection-in-renal-transplantation/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences